The conclusion of expert meeting "New treatment perspectives of community-acquired pneumonia and bacterial sinusitis"

1. Зетамакс ретард зарегистрирован в России по показаниям: внебольничная пневмония и острый бактериальный синусит. Инструкция по медицинскому применению препарата Зетамакс ретард одобрена Роздравнадзором 28.07.2006 № 57-Пр-рег/06.

2. Murray J.J. et al. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol. Head. Neck. Surg. 2005; 133: 194–201.

3. Drehobl M.A., Salvo M.C., Lewis D.E., Breen J.D. Singledose azitromycin microspheres vs. clarithromycin extended release for the treatment of mild-to-moderate community acquired pneumonia in adults. Chest 2005; 128: 2230–2237.

4. D'Ignazio J., Camere M. A., Lewis D.E. et al. Novel, singledose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob. Agents Chemother. 2005; 49 (10): 4035–41

5. FDA. Labeling Requirements for Systemic Antibacterial Drug Products Intended for Human use. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/00n-1463nfr00001.pdf

6. Kardas P., Devine S., Golembesky A., Roberts C. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Inter. J. Antimicrob. Agents 2005. 26: 106–113.